Search results for "Neoplastic"

showing 10 items of 2901 documents

Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38…

2019

IF 3.287 (2017); International audience; IntroductionCombination of cisplatine and Gemcitabine (CisGem) is the reference 1st line Chemotherapy in patients with advanced biliary cancer. FOLFIRINOX demonstrated an overall survival superiority when compared to gemcitabine in 1st line for patients with metastatic pancreatic adenocarcinoma. Because of similarities between pancreatic and biliary cancers, we proposed a randomized trial comparing mFOLFIRINOX and CisGEm.AimPRODIGE38-AMEBICA is a phase II/III trial evaluating efficacy of modifed FOLFIRINOX (D1 bolus removed) or CisGEm on patients with locally advanced non resectable or metastatic biliary tract cancer.Patients and methodsMain inclusio…

Malemedicine.medical_specialtyFOLFIRINOXmedicine.medical_treatmentModified folfirinoxLeucovorinAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/CancerAdvanced biliary cancerIrinotecanDeoxycytidineGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsCarcinomaHumansMedicineNeoplasm InvasivenessNeoplasm StagingChemotherapyHepatologybusiness.industryGallbladderCarcinomaGastroenterologyMetastatic Pancreatic Adenocarcinomamedicine.diseaseGemcitabinePrimary tumorGemcitabine3. Good healthOxaliplatinmedicine.anatomical_structureBile Duct NeoplasmsBiliary tract030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologyFluorouracilFranceCisplatinDrug Monitoringbusinessmedicine.drug
researchProduct

Gastrointestinal stromal tumour of the rectum: Report of a case and review of literature

2008

Gastrointestinal stromal tumour (GIST) is a rare tumour of the gastrointestinal tract which does not generally originate in the rectum. The authors describe a case of a 70-year-old man who underwent an anterior resection of the rectum for a low-risk GIST. The patient was not given adjuvant chemotherapy with imatinib and is still disease-free 30 mo after surgery. The authors conclude that although rectal GIST is extremely uncommon, it should be included in differential diagnosis when a tumour in the rectum is detected. Biopsy of the tumour is essential, since this makes it possible to reach a sure preoperative diagnosis based on the immunohistological features of the CD117 and CD34. Although…

Malemedicine.medical_specialtyGastrointestinal Stromal TumorsCD34RectumAntigens CD34Antineoplastic AgentsCase ReportPiperazinesGIST;BiopsymedicineHumansneoplasmsAgedGastrointestinal tractGiSTmedicine.diagnostic_testbiologyRectal NeoplasmsCD117business.industryGastroenterologyGeneral MedicineCombined Modality Therapydigestive system diseasesSurgeryProto-Oncogene Proteins c-kitPyrimidinesTreatment Outcomemedicine.anatomical_structureImatinib mesylateBenzamidesImatinib Mesylatebiology.proteinDifferential diagnosisbusinessGISTWorld Journal of Gastroenterology
researchProduct

Deep sclerectomy versus punch trabeculectomy: effect of low-dosage mitomycin C.

2004

<i>Purpose:</i> To compare IOP behavior after deep sclerectomy (DS) and trabeculectomy with the Crozafon-De Laage Punch (TP), using low-dosage intraoperative mitomycin C (MMC) in both techniques. <i>Methods:</i> The study was a prospective randomized clinical trial. All patients met inclusion and exclusion criteria, and were scheduled for glaucoma surgery. Forty patients were randomized to undergo either a nonpenetrating DS with MMC (DSMMC) (19 eyes) or a TP with MMC (TPMMC) (21 eyes). Postoperative examinations were performed at the 1st day, the 1st, 2nd and 3rd weeks and the 1st, 3rd, 6th, 9th and 12th months. Postoperative complications, number of antiglaucoma med…

Malemedicine.medical_specialtyLow dosagemedicine.medical_treatmentMitomycinTreatment outcomeGlaucomaTrabeculectomyExfoliation SyndromeDeep sclerectomyDeep sclerectomyOphthalmologymedicineTrabeculectomyHumansProspective Studiespunch trabeculectomyIntraocular PressureAgedAntibiotics Antineoplasticintegumentary systembusiness.industrySettore MED/30 - Malattie Apparato VisivoMitomycin CGeneral Medicinemedicine.diseaseSensory SystemsSurgeryOphthalmologyTreatment OutcomeSclerostomyFemalelow-dosage mitomycin CSafetybusinessGlaucoma Open-AngleOphthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
researchProduct

Influence of the Geriatric Oncology Consultation On the Final Therapeutic Decision In Elderly Subjects With Cancer: Analysis of 191 Patients

2014

International audience; Objectives: evaluate the impact of the Geriatric Oncology consultation on the final therapeutic management of cancer in elderly patients aged 70 and older. Design: retrospective study. Setting: the Pilot coordination unit in Geriatric Oncology of Cote d'Or, Burgundy, France. Participants: From January 2010 to December 2010, 191 patients with cancer aged 70 and older. Measurements: the concordance between the treatments proposed following the tumor Board, those proposed following the Geriatric evaluation (GE) and those actually given to the patients was evaluated using the kappa agreement test. Results: One hundred and ninety-one patients were included. Mean age was 8…

Malemedicine.medical_specialtyLung NeoplasmsConcordanceDecision MakingMedicine (miscellaneous)Breast NeoplasmsILLNESSMedical OncologyCONTROLLED-TRIALVALIDATIONlaw.inventionRandomized controlled triallawNeoplasmsPhysiciansmedicineMANAGEMENTHumansPhysician's RoleGeriatric AssessmentReferral and ConsultationSCALEAgedRetrospective StudiesQuality of Life ResearchAged 80 and overNutrition and Dieteticsbusiness.industryGeriatrics gerontologyUNDERTREATMENTAntineoplastic ProtocolsCancersocial sciences[SCCO] Cognitive sciencemedicine.diseasehumanitiesGeriatric oncologyGeriatricsFamily medicinePhysical therapyFemaleFrance[ SCCO ] Cognitive scienceGeriatrics and GerontologyColorectal Neoplasmsbusiness
researchProduct

Efficacy and safety of yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for auto…

2007

A prospective, multicenter, nonrandomized phase 2 trial was conducted to evaluate the efficacy and safety of a single dose of yttrium-90 (90Y) ibritumomab tiuxetan in elderly patients in first relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) ineligible for stem-cell transplantation. Patients had been previously treated with chemotherapy (group A, n = 76) or chemotherapy plus rituximab (group B, n = 28). Patients in group A were further divided into patients in whom induction therapy had failed (stratum AI, n = 33) and patients who had relapsed after achieving complete response (CR; stratum AII, n = 43). The overall response rate (ORR) was 52% and 53% in strata AI and AII…

Malemedicine.medical_specialtyLymphoma B-Cellmedicine.medical_treatmentImmunologyIbritumomab tiuxetanSalvage therapyAuthor Keywords:RadioimmunotherapyBiochemistryGastroenterologyAntibodies Monoclonal Murine-DerivedTRIAL Author InformationAutologous stem-cell transplantationRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineRefractory Diffuse Large B-Cell LymphomaHumansYttrium RadioisotopesY-90-ibritumomab tiuxetanHematologic toxicity KeyWords Plus:B-CELL LYMPHOMAAuthor Keywords:Radioimmunotherapy; Y-90-ibritumomab tiuxetan; Hematologic toxicity KeyWords Plus:B-CELL LYMPHOMA; LOW-GRADE; RADIOIMMUNOTHERAPY; INDOLENT; TRIAL Author InformationAgedCerebral HemorrhageAged 80 and overSalvage TherapyChemotherapybusiness.industryRemission InductionAntibodies MonoclonalCell BiologyHematologyRADIOIMMUNOTHERAPYINDOLENTmedicine.diseaseSurvival AnalysisLOW-GRADESurgeryTransplantationRituximabFemaleLymphoma Large B-Cell DiffusebusinessRituximabDiffuse large B-cell lymphomamedicine.drug
researchProduct

Malignant transformation of oral leukoplakia: a multicentric retrospective study in Brazilian population

2020

Background Among the oral potentially malignant disorders, leukoplakia stands out as the most prevalent. The purpose of this study was to analyse the clinical-pathological features of oral leukoplakia in groups of patients from three major pathology centers in two different regions of Brazil, in order to determine which factors would be associated to the clinical risk of malignant transformation. Material and Methods A total of 148 patients was analyzed, and data regarding gender, age, site, classification of the clinical subtype, harmful habits such as use of tobacco and alcohol, time of evolution and presence of dysplasia were collected. The association between risk factors and malignant …

Malemedicine.medical_specialtyMalignant transformationRisk FactorsTongueOral Cancer and Potentially malignant disordersInternal medicineStatistical significancemedicineHumansGeneral DentistryUNESCO:CIENCIAS MÉDICASRetrospective StudiesLeukoplakiabusiness.industryResearchRetrospective cohort studyMiddle Agedmedicine.diseasepediatric dentistryOral leukoplakiaExact testmucositisCell Transformation Neoplasticmedicine.anatomical_structureOtorhinolaryngologyDysplasiaoncologyFemaleSurgeryLeukoplakia OralbusinessBrazilMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Continuous Intravenous Administration of Granulocyte-Colony-Stimulating Factors—A Breakthrough in the Treatment of Cancer Patients with Febrile Neutr…

2021

(1) Background: Febrile neutropenia (FN) remains one of the most challenging problems in medical oncology and is a very severe side effect of chemotherapy. Its late consequences, when it is recurrent or of a severe grade, are dose reduction and therapy delays. Current guidelines allow the administration of granulocyte-colony-stimulating factors (G-CSF) for profound FN (except for the case when a pegylated form of G-CSF is administrated with prophylactic intention) in addition to antibiotics and supportive care. (2) Methods: This is a prospective study that included 96 patients with confirmed malignancy, treated with chemotherapy, who developed FN during their oncological therapy, and were h…

Malemedicine.medical_specialtyMedicine (General)Side effectmedicine.medical_treatmentNeutropeniaG-CSFfebrilechemotherapyGastroenterologyArticleProcalcitoninR5-920NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansneutropeniacancerProspective StudiesProspective cohort studyFebrile NeutropeniaChemotherapybiologybusiness.industryStandard treatmentC-reactive proteinGeneral Medicinemedicine.diseasebiology.proteinAdministration IntravenousFemalebusinessFebrile neutropeniaGranulocytesMedicina
researchProduct

Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Resul…

2018

Abstract Background and purpose Standard treatment of epidermoid anal cancer is 5-fluorouracil (5FU) and mitomycin C (MMC) based chemoradiotherapy (CRT). This phase I study aims to evaluate the addition of panitumumab (Pmab) to CRT and to determine the maximum tolerated dose (MTD) of Pmab and 5-FU in combination with CRT. Materials and methods Immunocompetent patients with locally advanced tumour without metastases (Stage T2, T3 or T4, whatever N stage; Stage N1–N3 whatever T stage) followed two RT periods (45 Gy in 5 weeks and 20 Gy in 2 weeks, separated by a 2-week break) with concomitant CT sessions of 5FU/MMC at RT weeks 1, 5 and 8. Pmab was administered on RT weeks 1, 3, 5, 8 and 10 ac…

Malemedicine.medical_specialtyMitomycinUrologyPhases of clinical research030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAnal cancerPanitumumabRadiology Nuclear Medicine and imagingProspective StudiesAgedbusiness.industryPanitumumabStandard treatmentMitomycin CChemoradiotherapyHematologyMiddle AgedAnus Neoplasmsmedicine.diseaseErbB ReceptorsOncology030220 oncology & carcinogenesisConcomitantT-stageFemaleFluorouracilbusinessChemoradiotherapymedicine.drugRadiotherapy and Oncology
researchProduct

Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study

2014

The outcome of high-risk (HR) Acute Lymphoblastic Leukemia (ALL) patients enrolled in AIEOP-BFM ALL 2000 study (NCT00613457) in Italy is described. Overall, 1999 Philadelphia negative ALL patients entered the study. HR criteria were: minimal residual disease (MRD) levels ≥10-3 at day 78 (HR-MRD), no complete remission (no-CR) at day 33, t(4;11) translocation, Prednisone Poor Response (PPR). Treatment (2 years) included protocol I, 3 polychemotherapy blocks, delayed intensification (protocol IIx2 or IIIx3), cranial radiotherapy, maintenance. 312 HR patients (15.6% of the total) had 5-year event-free survival (EFS) and overall survival (OS) of 58.9%(SE 2.8) and 68.9%(2.6). In hierarchical ord…

Malemedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmentImmunologyChromosomal translocationhigh riskacute lymphoblastic leukemiaHematopoietic stem cell transplantationBiochemistryGastroenterologyAdolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Neoplasm Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy; Remission Induction; Treatment Outcome; Hematology; Biochemistry; Cell Biology; ImmunologyPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy Protocolshigh risk; acute lymphoblastic leukemiaHumansMedicineNeoplasmPreschoolChildChemotherapyAntineoplastic Combined Chemotherapy ProtocolRadiotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationInfantCell BiologyHematologyPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCombined Modality TherapyMinimal residual diseaseSurgeryClinical trialRadiation therapyTreatment OutcomeN/ASettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAResidualChild PreschoolNeoplasmFemalebusinessHumanmedicine.drugBlood
researchProduct

Early detection of pneumonia in febrile neutropenic patients: use of thin-section CT.

1997

The purpose of this study was to evaluate the usefulness of thin-section CT for early detection of pneumonia in neutropenic patients with an unknown site of infection and normal or nonspecific findings on chest radiographs.Eighty-seven patients with febrile neutropenia that persisted for more than 2 days despite empiric antibiotic treatment underwent 146 prospective examinations. If findings on chest radiographs were normal (n = 126) or nonspecific (n = 20), thin-section CT (1-mm collimation, 10-mm increment) was done. If thin-section CT scans showed opacities, bronchoalveolar lavage was recommended.Findings on chest radiographs were nonspecific for pneumonia in 20 (14%) of 146 cases, and C…

Malemedicine.medical_specialtyNeutropeniaTime FactorsRadiographyAntineoplastic AgentsNeutropeniaFever of Unknown OriginPredictive Value of TestsRisk FactorsNeoplasmsmedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesMycosisLeukopeniamedicine.diagnostic_testbusiness.industryRespiratory diseasePneumoniaGeneral MedicineMiddle Agedmedicine.diseaserespiratory tract diseasesSurgeryPneumoniaBronchoalveolar lavageEvaluation Studies as TopicFemaleRadiologymedicine.symptomTomography X-Ray ComputedbusinessBronchoalveolar Lavage FluidFebrile neutropeniaAmerican Journal of Roentgenology
researchProduct